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Previews(del(5q) MDS). In one patient who pro-
gressed to AML, all of the newly acquired
mutations were detectable in the stem
cell compartment. In a second patient
with disease progression, oneof the newly
acquired mutations was detected in bulk
cells from the advanced lesion, but not in
the stem cell compartment, suggesting
that it was acquired in a downstream pro-
genitor that had acquired self-renewal po-
tential. Thus, paths to leukemic transfor-
mation can occur either in stem cells or
in progenitor cells.
These findings provide strong evidence
that mutations occurring in phenotypically
defined stem cells indeed drive the patho-
genesis of MDS. However, several ques-
tions remain unanswered. The authors
assume that mutations driving MDS
occurred in stem cells because they
found the mutations in cells defined by
having a particular set of surface markers.
Is it possible that acquisition of certain
mutations in committed progenitors ‘‘re-
programs’’ them to a stem cell phenotype,
expressing the canonical HSC surface
proteins? Which mutations must occur in
stem cells, and which can confer self-714 Cancer Cell 25, June 16, 2014 ª2014 Elsrenewal potential to committed progeni-
tors? Larger data sets, along with
functional experiments, will be needed to
answer these questions.
It has been suggested that therapies
eradicating the MDS stem cell are neces-
sary for curing disease. However, the
authors demonstrate that the stem and
progenitor compartment in low/interme-
diate risk MDS is minimally perturbed,
although the MDS clone has already
taken over the marrow at the time of dis-
ease presentation. Might therapies that
improve the functionality of the differenti-
ated progeny be effective? Nonetheless,
the work by Woll et al. (2014) does further
demonstrate that MDS is indeed a stem
cell disorder.REFERENCES
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GNAQ andGNA11 are frequently mutated in uveal melanoma, but they remain difficult therapeutic targets. In
this issue of Cancer Cell, Feng and colleagues and Yu and colleagues demonstrate that the oncogenic
activity of mutant GNAQ/11 ismediated at least in part through YAP, potentially uncovering a new therapeutic
strategy.Malignant melanomas that arise from the
iris, ciliary body, and choroid layers of
the eye—collectively referred to as uveal
melanomas—represent the most com-
mon primary cancer of the eye and the
second most common form of melanoma
(Harbour, 2012). Despite the availability
of highly effective treatments for eradi-cating the primary tumor, up to half of
affected individuals later develop meta-
static disease that is almost always fatal
within a few months. Until recently, the
identification of effective therapies for
metastatic uveal melanoma has been
hampered by a lack of known driver muta-
tions. This situation has changed in recentyears with the discovery of several com-
mon driver mutations, which has opened
the door to rational targeted therapies
(Harbour, 2012).
Mutually exclusive mutations in the G
protein-coupled receptor (GPCR) alpha
subunits GNAQ and GNA11 (encoding
Gq and G11 proteins, respectively) are
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Previewspresent in 85% of uveal melanocytic
tumors, including benign nevi, primary
melanomas of all stages, and metastatic
lesions (Van Raamsdonk et al., 2010).
This spectrum suggests that GNAQ/11
mutations occur early and may even
represent initiating events in tumorigen-
esis (Harbour, 2012). These mutations
occur as single amino acid substitutions
at residues Q209 or R183, and they abro-
gate the intrinsic GTPase activity that nor-
mally serves to inactivate the subunit. As
such, these inactivating mutations result
in constitutive activation of oncogenic
Gq/11 subunits. The recessive nature of
these mutations at the molecular level,
despite their dominant action at the
cellular level, has posed amajor challenge
for direct pharmacologic inhibition.
Instead, most efforts have focused on in-
hibiting downstream targets of activated
Gq/11. The best understood target of
Gq/11 is phospholipase C beta (PLCb),
which cleaves phosphatidylinositol (4,5)-
bisphosphate (PIP2) to yielddiacylglycerol
(DAG) and inositol triphosphate (IP3). Both
products promote stimulation of protein
kinase C (PKC), which leads to activation
of the mitogen-activated protein kinase
(MAPK or MEK) pathway and cell prolifer-
ation. MEK and PKC inhibitors inhibit the
proliferation of Gq/11 mutant uveal mela-
noma cell lines in vitro (Ambrosini et al.,
2012; Wu et al., 2012). Yet, clinical trials
so far have shown little or no activity of
such agents in patients with metastatic
uveal melanoma, raising the question of
whether there may be other targets that
are critical for therapeutic inhibition in can-
cers harboring oncogenic forms of Gq/11.
One such target may be the Hippo
tumor suppressor pathway, which con-
trols tissue growth and cell fate through
the regulation of cell proliferation and
apoptosis (Harvey et al., 2013). Key effec-
tors of the pathway include the homolo-
gous oncoproteins YAP and TAZ, which
promote tissue growth by regulating the
activity of transcription factors such as
TEADs and SMADs. In most proliferating
cells, YAP is localized in the nucleus in
its active form. Hippo pathway signaling
leads to phosphorylation of YAP by the
serine/threonine-protein kinases LATS1/
2, resulting in YAP inactivation and reten-
tion in the cytoplasm and degradation via
the proteasome.
In this issue of Cancer Cell, Feng et al.
(2014) and Yu et al. (2014) show thatGq/11 mutants found in uveal melanoma
promote tumorigenesis by activating
YAP. Mutant Gq/11, but not wild-type
Gq/11, was found to trigger dephosphor-
ylation and nuclear localization of YAP,
associated with YAP-dependent tran-
scription. Importantly, this activity of
mutant Gq/11 is independent of PLCb
(Feng et al., 2014). In uveal melanoma
cell lines and human tumor samples, there
was a strong correlation between the
presence of Gq/11 mutations and acti-
vated YAP, as indicated by its nuclear
localization and increased levels of un-
phosphorylated YAP (Yu et al., 2014).
The question then arises as to whether
this YAP activation by mutant Gq/11 is
mediated solely through inhibition of
LATS1/2. In their current article and in a
recent publication by the same group
(Vaque´ et al., 2013), Feng et al. (2014)
show that activation of YAP by mutant
Gq requires the guanine nucleotide ex-
change factor, Trio, and downstream
small GTPases RhoA and Rac1. Activa-
tion of RhoA and Rac1 induces actin poly-
merization of G-actin to F-actin, triggering
dissociation of the cytoskeletal-associ-
ated protein angiomotin (AMOT) from
YAP, thereby allowing YAP to translocate
from the cytoplasm to the nucleus to acti-
vate YAP-dependent transcription. Thus,
mutant Gq/11 may activate YAP not only
by inhibiting LATS1/2, but also by promot-
ing actin polymerization independently of
the canonical Hippo pathway.
A major implication of these findings
is that traditional GPCR signaling through
PLCb may not be the only, or even the
most important, mechanism for propa-
gating mutant Gq/11 activity. Pharmaco-
logic targeting of this novel YAP-depen-
dent pathway may be critical for effective
therapy against Gq/11 mutant cancers.
Prompted by the recent identification of
verteporfin as an inhibitor of YAP activity
(Liu-Chittenden et al., 2012), both groups
show that verteporfin inhibits the growth
of uveal melanomas in xenograft mouse
models (Feng et al., 2014; Yu et al.,
2014). Because verteporfin is a well-toler-
ated agent with a favorable systemic
toxicity profile, further work is warranted
to explore the therapeutic potential of
this and other porphyrin derivatives in
metastatic uveal melanoma.
Although these findings are promising, it
is unlikely that inhibition of mutant Gq/11
signalingalonewill be sufficient for treatingCancer Cellmetastatic uveal melanoma. Mutant Gq
and G11 are relatively weak oncoproteins
that are only able to transform immortal-
ized melanocytes that have been geneti-
cally altered to be deficient in the p53
andp16/CDK4/RBpathways (VanRaams-
donk et al., 2009). Further, the vast major-
ity of uvealmelanocytic tumorswithGq/11
mutations are benign and do not metasta-
size, indicating that they require additional
mutations to acquire metastatic potential.
Thus, it will likely be necessary to target
other driver mutations, perhaps in combi-
nation with Gq/11 inhibition. Because in-
activatingmutations in the tumor suppres-
sor BRCA1-associated protein 1 (BAP1)
are present in the vastmajority ofmetasta-
sizing uveal melanomas (Harbour et al.,
2010), BAP1 is a leading candidate for
such therapeutic targeting. Nevertheless,
these findings will play an important role
in the ongoing quest for effective therapy
against metastatic uveal melanoma.REFERENCES
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